American Kidney Fund Announces Partnership with Tricida to Expand Education of Metabolic Acidosis in Patients with Kidney Disease

ROCKVILLE, Md. (October 22, 2020) — The American Kidney Fund (AKF) today announced a partnership with Tricida, Inc. to increase the understanding of chronic metabolic acidosis, a common complication of kidney disease that can cause serious effects, such as chronic kidney disease (CKD) progression, muscle atrophy and cardiac issues. Tricida's support will allow AKF to develop and disseminate educational information about metabolic acidosis' role in the progression of CKD.

"Complications of CKD, such as metabolic acidosis, create serious health problems, including patients' kidney disease getting worse," said LaVarne A. Burton, AKF president and CEO. "We are extraordinarily grateful to Tricida for its partnership in working with us to encourage patients to take metabolic acidosis management seriously."

"Tricida is honored to partner with the American Kidney Fund on this critical effort to increase awareness and understanding of metabolic acidosis in those with kidney disease," said Gerrit Klaerner, PhD, Tricida CEO and president. "We estimate that in the US, approximately 3 million patients with CKD have metabolic acidosis, and this initiative aligns with our goal to slow CKD progression by reducing the prevalence and severity of metabolic acidosis in these patients with kidney disease."

Metabolic acidosis is a buildup of acid in the body, which is common in people with kidney disease because their kidneys are not filtering their blood well enough. Patients with kidney disease may have too much acid because their kidneys are not sufficiently removing it or because their body may be producing an excessive amount of acid.